Orexo

    OverviewSuggest Edit

    Orexo, a specialty pharmaceutical company, engages in the development and commercialization of drugs. Its products include Zubsolv tablets for the treatment of opioid dependence; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar, an active substance zolpidem that is used for the treatment of short-term insomnia. The Company's development projects comprise OX382, oral formulation of buprenorphine; OX-CLI, a novel treatment of respiratory disorders, such as asthma and COPD; OX-MPI, for inflammatory related pain; and OX51, a sublingual formulation containing alfentanil for the prevention of acute pain during short surgical and diagnostic procedures.

    TypePublic
    Founded1995
    HQUppsala, SE
    Websiteorexo.com

    Latest Updates

    Employees (est.) (Nov 2018)89(+2%)

    Orexo Office Locations

    Orexo has an office in Uppsala
    Uppsala, SE (HQ)
    7E Rapsgatan
    Show all (1)

    Orexo Online and Social Media Presence

    Embed Graph

    Orexo News and Updates

    Report from Orexo AB's Annual General Meeting

    UPPSALA, Sweden, April 11, 2019 /PRNewswire/ -- Election of the board of directors and auditor The annual general meeting in Orexo AB (publ) on 11 April 2019 resolved, in accordance with the nomination committee's proposal, that the number of board members shall be eight with no deputy...

    Orexo Publishes the Annual Report for 2018

    UPPSALA, Sweden, March 21, 2019 /PRNewswire/ -- Orexo's Annual Report, including the Sustainability Report, for the 2018 fiscal year has been published and can be downloaded on the company's website, www.orexo.com (investors/reports, presentations and audiocasts). A PDF version is also...

    Orexo Publishes the Annual Report for 2018

    UPPSALA, Sweden, March 21, 2019 /PRNewswire/ -- Orexo's Annual Report, including the Sustainability Report, for the 2018 fiscal year has been published and can be downloaded on the company's website, www.orexo.com (investors/reports, presentations and audiocasts). A PDF version is also...

    Orexo Regains Rights to Zubsolv® in all Countries Outside the US

    UPPSALA, Sweden, Dec. 13, 2018 /PRNewswire/ -- Orexo AB (publ.), the fully integrated specialty pharmaceutical company addressing opioid addiction and pain, today announces that the Company will regain the rights to Zubsolv (buprenorphine and naloxone sublingual tablet) for the treatment...

    Orexo Hosts Capital Markets Day Today in Stockholm, Sweden

    UPPSALA, Sweden , Dec. 6, 2018 /PRNewswire/ -- Orexo AB (publ.), the fully integrated specialty pharmaceutical company addressing opioid addiction and pain, is today hosting the Company's Capital Markets Day for investors, analysts and media in Stockholm, Sweden. Orexo's management team...

    Agenda - Orexo Capital Markets Day, Stockholm, Sweden, Dec. 6

    UPPSALA, Sweden, Nov. 28, 2018 /PRNewswire/ -- Orexo AB (publ.), the specialty pharmaceutical company, invites as earlier communicated investors, analysts and media to its Capital Markets Day in Stockholm, Sweden, on December 6, at Armémuseet, Riddargatan 13. The agenda of the day is...
    Show more

    Orexo Frequently Asked Questions

    • When was Orexo founded?

      Orexo was founded in 1995.

    • How many employees does Orexo have?

      Orexo has 89 employees.

    • Who are Orexo competitors?

      Competitors of Orexo include CytomX Therapeutics, PharmScript and Lescarden.

    • Where is Orexo headquarters?

      Orexo headquarters is located at 7E Rapsgatan, Uppsala.

    • Where are Orexo offices?

      Orexo has an office in Uppsala.

    • How many offices does Orexo have?

      Orexo has 1 office.